A cost evaluation of treatment alternatives for mild‐to‐moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil
暂无分享,去创建一个
[1] A. Kiadaliri,et al. The impact of inhibitors on the cost of clotting factor replacement therapy in hemophilia A in south of Iran. , 2009 .
[2] J. Astermark,et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. , 2007, Blood.
[3] C. Négrier,et al. A retrospective postlicensure survey of FEIBA efficacy and safety , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.
[4] L. Aledort,et al. Therapeutic decision‐making in inhibitor patients , 2006, American journal of hematology.
[5] M. Botteman,et al. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors* , 2006, Current medical research and opinion.
[6] C. Knight. Health economics of treating haemophilia A with inhibitors , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.
[7] K. Kavaklı,et al. A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey , 2005 .
[8] J. Avorn,et al. The economic impact of factor VIII inhibitors in patients with haemophilia , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.
[9] S. Paisley,et al. Economic modelling of different treatment strategies for haemophilia A with high‐responding inhibitors , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.
[10] J. Journeycake,et al. Coagulation disorders. , 2003, Pediatrics in review.
[11] J. Guest,et al. Modelling the economic impact of recombinant activated Factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX in the UK , 2002 .
[12] J. Guest,et al. Modelling the economic impact of recombinant activated Factor VII and activated prothrombin-complex concentrate in the treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX at a comprehensive care centre in the UK , 2002 .
[13] Blanchette,et al. The impact of inhibitors on the cost of clotting factor replacement therapy in haemophilia A in Canada , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.
[14] J. Gill,et al. Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors , 1998, Thrombosis and Haemostasis.
[15] J. Goudemand. Le facteur VII activé recombinant: un nouveau traitement de l'hémophilie , 1998 .
[16] J. Dixon. Other national models , 1998 .
[17] J. Goudemand. [Recombinant activated factor VII: a new treatment for hemophilia]. , 1998, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.
[18] C. Rothschild,et al. Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors , 1997, Thrombosis and Haemostasis.
[19] M. Hilgartner,et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII , 1993, The Lancet.
[20] M. Hilgartner,et al. Efficacy and safety of vapor‐heated anti‐inhibitor coagulant complex in hemophilia patients. FEIBA Study Group , 1990, Transfusion.
[21] G. Knatterud,et al. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. , 1983, Blood.
[22] H. V. van Houwelingen,et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. , 1981, The New England journal of medicine.
[23] 三澤吉雄. In Canada … , 1980, Current History.
[24] Aishwarya G. Jacob,et al. THE INHIBITORS , 2021 .